Answers are grounded in this paper and cite their sources.
Secondary analysis shows older patients with advanced cancer value quality of life over extending survival, suggesting a shift in treatment focus.
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, most older patients with advanced cancer are prioritizing quality of life over extending survival, according to a secondary analysis. In addition, Ipsen has voluntarily withdrawn tazemetostat from the market after a recommendation from an independent data monitoring committee showed an increase in the risk for secondary hematologic malignancies, and the FDA approves nivolumab and a chemotherapy combination for previously untreated Hodgkin lymphoma.
No takes yet. Share an insight, caveat, or question.
Leah Lawrence (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: